Greg is currently Senior Director of Biologics Process Development at Eisai Inc. Greg has over 25 years of progressive leadership roles in Operations, Process Development/Validation and Quality Assurance in clinical and commercial biopharmaceutical bulk drug substance and drug product production settings. His experience spans both large and small biotech companies including facility start-up, renovation and qualification to meet international regulatory and compliance requirements. Greg has a strong background in the development, scale-up, technology transfer and cGMP manufacture of monoclonal antibodies, microbial expressed proteins and antibody-drug conjugates, along with broad based knowledge of the biopharmaceutical industry as a whole. Greg earned both his Bachelor of Science degree in Biology and an MBA from the Pennsylvania State University. His interest is to contribute to the Delaware Valley Chapter in identification and delivery of high-level, relevant content of interest to our members.